Table 4.

Treatments with published clinical trials for mild-to-moderate COVID-19 non-hospitalized adults with high risk factors for sCOVID-19.

Treatment and Authors	Primary Endpoints	Efficacy (All Values in %)	Dosing and Route of Administration
Paxlovid-Hammond et al. [131]	28-day incidence all-cause hospitalization or mortality.	0.7 Tx vs. 6.5 placebo; rRR, 88 (p < 0.0001).	300 mg nirmatrelvir and 100 mg ritonavir oral BID × 5 days.
Molnupiravir-Jayk Bernal et al. [132]	29-day incidence all-cause hospitalization or mortality.	6.8 Tx vs. 9.7 placebo; rRR, 30 (p = 0.022).	800 mg at four 200 mg capsules oral BID × 5 days.
Remdesivir-Gottlieb et al. [133]	28-day incidence of all-cause hospitalization or mortality.	0.7 Tx vs. 5.3 placebo; hazard ratio, 0.13 (p = 0.008).	200 mg IV for 1 day, 100 mg IV, for next 2 days.
Fluvoxamine-Reis et al. [134]	28-day incidence of all-cause hospitalization, defined as retention in ER setting for >6 h or transfer to a tertiary hospital due to COVID-19.	11.0 Tx vs. 16 placebo; rRR, 68.0 (p = 0.002).	100 mg oral BID × 10 days.
Convalescent Plasma–Sullivan et al. [135]	28-day incidence of all-cause hospitalization	2.9 Tx vs. 6.3 placebo; absolute risk reduction, 3.4; 95% CI, 1.0–5.8; p = 0.005	250 mL transfusion over 1 h, followed by 30 min of observation
REGEN-COV- Weinreich et al. [136]	29-day incidence of all-cause hospitalization or mortality.	4.0 Tx vs. 3.2 placebo; rRR, 70.4 (p = 0.002).	1200 mg single dose, IV (600 mg casirivimab, 600 mg imdevimab).
Bamlanivimab/Etesevimab- Dougan et al. [137]	29-day incidence of all-cause hospitalization or mortality.	2.1 Tx vs. 7.0 placebo; rRR, 70.0 (p < 0.001).	5600 mg single dose, IV (2800 mg bamlanivimab/2800 mg etesivimab).
Sotrovimab Gupta et al. [138]	29-day incidence of all-cause hospitalization or mortality.	1.0 Tx vs. 7.0 placebo; rRR, 85.0 (p = 0.002).	500 mg single dose, IV

IV: intravenous, rRR: relative risk reduction, Tx: treatment.